<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03344263</url>
  </required_header>
  <id_info>
    <org_study_id>VISA</org_study_id>
    <nct_id>NCT03344263</nct_id>
  </id_info>
  <brief_title>Study of the Reversibility of Vigilance Dysfunction at 6 Months of Continuous Positive Airways Pressure (CPAP) in Patients With Obstructive Sleep Apnea/Hypopnea Syndrome (OSAHS)</brief_title>
  <acronym>VISA</acronym>
  <official_title>Study of the Reversibility of Vigilance Dysfunction at 6 Months of Continuous Positive Airways Pressure (CPAP) in Patients With Obstructive Sleep</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Poitiers University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Poitiers University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is a monocentric prospective pilot study in Poitiers University Hospital, specifically&#xD;
      analyzing the vigilance disorders in the Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS)&#xD;
      and their reversibility after 6 months of Continuous positive airways pressure (CPAP).&#xD;
&#xD;
      All subjects were administered a test of vigilance (Test of Attentional Performance) both&#xD;
      before and after the 6 months of CPAP.&#xD;
&#xD;
      The main objective is the study of the reversibility of alertness disorders on the number of&#xD;
      omissions in the subtest visual vigilance of the TAP ( (Test of Attentional Performance) at 6&#xD;
      months of CPAP in the OSAHS in patients with a memory complaint.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 17, 2017</start_date>
  <completion_date type="Anticipated">February 17, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 17, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Study of the reversibility of vigilance disorders on the number of omissions in the subtest visual vigilance of the TAP</measure>
    <time_frame>After 6 months of continuous positive airways pressure in the OSAHS patient</time_frame>
    <description>Reversibility of vigilance disorders on the number of omissions in the subtest visual vigilance of the TAP</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Vigilance Dysfunction</condition>
  <arm_group>
    <arm_group_label>tests of attentional performance</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>tests of attentional performance</intervention_name>
    <description>tests of attentional performance before and after 6 months of continuous positive airways pressure</description>
    <arm_group_label>tests of attentional performance</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients aged 20-70 years&#xD;
&#xD;
          -  Memory disorders without memory problems in episodic memory&#xD;
&#xD;
          -  Presence of polysomnography of a obstructive sleep apnea/hypopnea syndrome (OSAHS)&#xD;
             requiring Continuous positive airways pressure&#xD;
&#xD;
               -  Moderate OSAHS (Apnea Hypopnea Index ≥ 15 / hour with arousals ≥ 10)&#xD;
&#xD;
               -  Severe OSAHS (Apnea Hypopnea Index ≥ 30 / h)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt;20 years or ≥ 70 years&#xD;
&#xD;
          -  Neurodegenerative disease (Alzheimer's disease, Parkinson's disease)&#xD;
&#xD;
          -  Dysthyroidism&#xD;
&#xD;
          -  Severe depression, schizophrenia, bipolar disorder&#xD;
&#xD;
          -  Treatment with an effect on cognition: hypnotics, sedative&#xD;
&#xD;
          -  Chronic Obstructive Pulmonary Disease&#xD;
&#xD;
          -  Chronic alcoholism, other addictions&#xD;
&#xD;
          -  Contraindications to Magnetic Resonance Imaging&#xD;
&#xD;
          -  Refusal of equipment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>service de neurologie CHU DE POITIERS</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 13, 2017</study_first_submitted>
  <study_first_submitted_qc>November 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2017</study_first_posted>
  <last_update_submitted>November 16, 2020</last_update_submitted>
  <last_update_submitted_qc>November 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

